These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24696723)

  • 1. Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation.
    Peng WX; Kudo M; Fujii T; Teduka K; Naito Z
    Int J Clin Exp Pathol; 2014; 7(3):1069-76. PubMed ID: 24696723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells.
    Matsuda Y; Hagio M; Seya T; Ishiwata T
    Mol Cancer Ther; 2012 Sep; 11(9):2010-20. PubMed ID: 22778155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
    J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
    Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
    Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.
    Sengal AT; Smith D; Snell CE; Leung S; Talhouk A; Williams ED; McAlpine JN; Pollock PM
    J Pathol Clin Res; 2022 Nov; 8(6):521-537. PubMed ID: 35866380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.
    Planagumà J; Díaz-Fuertes M; Gil-Moreno A; Abal M; Monge M; García A; Baró T; Thomson TM; Xercavins J; Alameda F; Reventós J
    Cancer Res; 2004 Dec; 64(24):8846-53. PubMed ID: 15604243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
    Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
    FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters.
    Hakim SA; Raboh NM
    Int J Clin Exp Pathol; 2015; 8(10):13225-32. PubMed ID: 26722522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammaglobin B expression in human endometrial cancer.
    Tassi RA; Bignotti E; Falchetti M; Calza S; Ravaggi A; Rossi E; Martinelli F; Bandiera E; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2008; 18(5):1090-6. PubMed ID: 18021217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.
    Bignotti E; Ravaggi A; Romani C; Falchetti M; Lonardi S; Facchetti F; Pecorelli S; Varughese J; Cocco E; Bellone S; Schwartz PE; Rutherford TJ; Santin AD
    Int J Gynecol Cancer; 2011 Dec; 21(9):1613-21. PubMed ID: 21892093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.
    de Sousa VP; Chaves CB; Huguenin JF; Moreira FC; de Reis BS; Chimelli L; Bergmann A; Simão Tde A; Pinto LF
    Cancer Biol Ther; 2014 Jul; 15(7):888-94. PubMed ID: 24756106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
    Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
    Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
    Arafa M; Kridelka F; Mathias V; Vanbellinghen JF; Renard I; Foidart JM; Boniver J; Delvenne P
    Histopathology; 2008 Nov; 53(5):525-32. PubMed ID: 18783461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
    Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
    Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.